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in each country. Latanoprost was 3% less expensive than
bimatoprost and travoprost in Norway and Sweden, and the
costs of the 3 agents were within 1% of each other in Denmark.
Latanoprost dominated (i.e., was more effective and less expen-
sive than) bimatoprost and travoprost in Norway and Sweden.
In Denmark, bimatoprost dominated travoprost. Although
bimatoprost was slightly less expensive than latanoprost in
Denmark (DKK 28,700 vs 29,000, respectively), latanoprost was
more effective yielding an incremental cost-effectiveness ratio of
DKK 47,871. CONCLUSIONS: In Scandinavia, latanoprost was
more cost-effective than other available prostaglandin analogues
over a 5-year period.
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OBJECTIVE: To assess the relative cost-effectiveness of
monotherapy with latanoprost or timolol in the treatment of
open-angle glaucoma in Denmark, Norway, Sweden (Scandi-
navia), and the UK (UK). METHODS: Cost-effectiveness analy-
sis was performed using a Markov model. The health states were
stable and progressed glaucoma. Transition probabilities for
primary open-angle and exfoliation glaucoma were derived from
the medical literature, and data concerning practice patterns
were obtained from surveys completed by 54 ophthalmologists
geographically dispersed throughout each of the countries.
Country-speciﬁc unit costs were assigned for medications,
patient visits, diagnostics, and therapeutic procedures. Quality
of life weights for various levels of visual acuity ranged from 0.50
to 0.68. A payer perspective with a 5-year time horizon was
adopted and costs were discounted at 3% for Scandinavia or
3.5% for the UK per year. RESULTS: Latanoprost was less
expensive than timolol, ranging from 5.4% to 6.7% less in Scan-
dinavia and by 2.1% less in the UK. The range of effectiveness
(years to progression of glaucoma) between treatment cohorts
was narrow, from 0.003 to 0.01, which may have reﬂected the
fact that the design assumed that physicians control most
patients’ glaucoma over 5 years by adding or changing therapy.
Incremental cost-effectiveness ratios for latanoprost versus
timolol were DKK 447,857 in Denmark, NOK 457,212 in
Norway, SEK 1,251,126 in Sweden, and GBP 6087 in the UK.
CONCLUSIONS: Over a 5-year period, latanoprost monother-
apy is as cost-effective as traditional timolol generics in Scandi-
navia and the UK.
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OBJECTIVES: To estimate the cost-effectiveness of pegaptanib
versus best supportive care for age-related macular degeneration
(ARMD) in the UK and to evaluate the impact of patient char-
acteristics. METHODS: A 10-year Markov model was con-
structed composed of 13 health states, 12 visual acuity (VA)
states deﬁned by individual Snellen lines and death. Time-
dependent transition probabilities for the loss and gain of Snellen
lines were derived from parametric survival models ﬁtted to
patient-level data from the VISION trial. Survival models were
ﬁtted with treatment group and baseline Snellen score as covari-
ates, and other models were ﬁtted with the addition of age,
gender, and lesion type or lesion size. Mortality rates were
adjusted for the age and gender of the model population. Utility
weights elicited using a choice-based method were derived from
the published literature. Resource use estimates were developed
by structured interview of three consultant ophthalmologists.
Other model parameters were obtained from the published lit-
erature; unit costs were obtained from national sources (cost year
2005). Uncertainty was explored by probabilistic and univariate
sensitivity analysis. RESULTS: In the base-case analysis, treat-
ment was targeted to patients with VA of 20/40 to 20/320 and
was discontinued if VA fell below 20/320 or by 6 or more lines.
The incremental cost per quality adjusted life year gained
(IC/QALY) was estimated as £8023 [upper 95% CI: £20,641].
Age had the greatest impact [age <75: £2033/QALY; age ≥75:
£11,657/QALY]. Pre-treatment VA was also important [20/40 to
20/320: £8023/QALY; 20/40 to 20/200: £6664/QALY]. Gender,
lesion type, and lesion size had little effect on the IC/QALY [all
estimates were between £7000 and £9000/QALY]. CONCLU-
SIONS: Pegaptanib treatment is expected to be cost-effective
across all groups studied, and marginally more cost-effective in
younger patients and those with better pre-treatment VA.
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OBJECTIVES: To determine the impact of differences in 
care and services provided to the visually impaired in the UK
(UK) and the United States (US) on the cost-effectiveness of
pegaptanib in age-related macular degeneration (ARMD).
MEHTODS: A Markov model was used to model the visual
acuity of a cohort of ARMD patients over a period of 10 years.
Country-speciﬁc data for the US and UK included mortality
rates, treatment-related costs, adverse event treatment patterns,
costs associated with excess cases of depression and injury, and
services provided to the visually impaired. In the UK, these con-
sisted of visual aids and rehabilitation, community and residen-
tial care, and social security beneﬁts. In the US, these included
all Medicare costs including skilled nursing facility and nursing
home care. Social security beneﬁts have not been quantiﬁed in
the US and could not be included. RESULTS: The incremental
beneﬁt of pegaptanib was slightly higher in the US than the UK
due to the slightly greater life expectancy (incremental quality-
adjusted life year [QALY] estimates were 0.302 and 0.297,
respectively). The average per patient cost associated with the
provision of services to those with visual impairment was similar
when social security beneﬁts were excluded but substantially
lower in the US than the UK when they were included ($24,815
and GBP 25,014 [∼$46,326] per patient receiving standard care,
respectively). This resulted in higher incremental cost/QALY 
estimates in the US than the UK ($37,607 and GBP 8023
[∼$14,842], respectively). CONCLUSION: Pegaptanib is
expected to be cost-effective at recognized thresholds in both
health care systems, despite differences in the provision of health
and personal care. Cost-effectiveness in the US may be underes-
timated due to the lack of information on the cost of social secu-
rity beneﬁts for the visually impaired.
